Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2011-01-25Clinical Trial Update: A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer [Phase 1]
Phase I study of BMS-641988 in Japanese patients with castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2011-01-07Clinical Trial Update: Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates [Phase 2]
Phase 2 trial update of denosumab (AMG 162) in patients with advanced cancer and bone metastases who were receiving IV bisphosphonates; resu…
-
CLINICAL_TRIALS trial_result · 2010-12-23Clinical Trial Update: XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer [Phase 3]
Phase 3 trial comparing XRP6258 plus prednisone vs mitoxantrone plus prednisone in hormone-refractory metastatic prostate cancer; results we…
-
CLINICAL_TRIALS trial_result · 2010-11-09Clinical Trial Update: A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) [Phase 2]
Phase 2 trial in chemotherapy‑naïve metastatic castration-resistant prostate cancer comparing AT-101 plus docetaxel and prednisone versus do…
-
CLINICAL_TRIALS trial_result · 2010-11-01Clinical Trial Update: Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy [Phase 3]
Phase 3 results for sipuleucel-T (Provenge) vaccine therapy in metastatic castration-resistant prostate cancer were posted, representing piv…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2010-08-24Clinical Trial Update: A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating AT-101 as a single agent in men with castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS research · 2010-08-18Clinical Trial Update: Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer [Phase 2]
This entry reports on a Phase 2 biomarker study evaluating the combination of sunitinib and docetaxel in castration-resistant prostate cance…
-
FDA approval · 2010-06-17FDA Approved: JEVTANA — Original Application (Sanofi-Aventis U.S. LLC)
The FDA approved JEVTANA (cabazitaxel) in the original NDA submitted by Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2010-05-26Clinical Trial Update: Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) [Phase 2]
This Phase 2 trial tested mitoxantrone plus prednisone with sorafenib in taxane-refractory metastatic castration-resistant prostate cancer, …
-
CLINICAL_TRIALS trial_result · 2010-04-08Clinical Trial Update: Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone [Phase 1]
Phase 1 safety update on LBH589 (panobinostat) alone and with intravenous docetaxel and prednisone in men with hormone-refractory prostate c…
-
CLINICAL_TRIALS trial_result · 2009-10-27Clinical Trial Update: Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer [Phase 2]
A Phase 2 trial comparing docetaxel alone versus docetaxel plus estramustine in men with hormone-refractory (castration-resistant) metastati…
-
CLINICAL_TRIALS trial_result · 2009-10-01Clinical Trial Update: Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer [Phase 2]
Phase 2 trial in Japan evaluating the combination of docetaxel and prednisolone for metastatic castration-resistant prostate cancer has comp…
-
CLINICAL_TRIALS trial_result · 2009-07-31Clinical Trial Update: Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients [Phase 2]
Phase 2 trial evaluating fermented wheat germ extract (FWGE) in combination with hormone therapy for hormone-refractory prostate cancer; the…
-
CLINICAL_TRIALS research · 2009-07-28Clinical Trial Update: Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy
A clinical trial update evaluating whether circulating tumor cells predict survival in hormone-refractory (castration-resistant) prostate ca…
-
CLINICAL_TRIALS trial_result · 2009-03-30Clinical Trial Update: Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients. [Phase 1]
A Phase 1 dose-seeking trial of PCK3145 in asymptomatic, castration-resistant metastatic prostate cancer patients has completed.
-
CLINICAL_TRIALS trial_result · 2009-03-27Clinical Trial Update: PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone [Phase 2]
Phase II non-comparative trial in metastatic castration-resistant prostate cancer evaluating a therapy in combination with prednisolone. The…
-
CLINICAL_TRIALS research · 2009-03-12Clinical Trial Update: ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere [Phase 2, Phase 3]
This is an update on the ASCENT trial evaluating calcitriol in combination with Taxotere (docetaxel) for prostate cancer, specifically castr…
-
CLINICAL_TRIALS trial_result · 2009-02-20Clinical Trial Update: Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients [Phase 2]
A completed Phase II multi-center trial comparing MER-101 20 mg tablets to intravenous zoledronic acid (Zometa) 4 mg in bisphosphonate-naive…
-
CLINICAL_TRIALS trial_result · 2008-11-25Clinical Trial Update: Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer [Phase 2]
A Phase 2 study assessing the efficacy and pharmacodynamics of Panzem NCD in patients with hormone-refractory prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2008-01-15Clinical Trial Update: MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer [Phase 2]
This document provides an update on a Phase 2 trial evaluating MEDI-522 in patients with metastatic castration-resistant prostate cancer.